News & Analysis on Clinical Trial Services & Contract Research And Development
Calliditas Therapeutics says it is optimistic about getting full marketing authorization for a drug to treat primary IgA nephropathy (IgAN) after submitting a request to the European Medicines Agency (EMA).
A study to evaluate the effect of seladelparm, a small molecule treatment by CymaBay Therapeutics, Inc. on patients with cirrhosis was announced this month (September 21).
The first treatment for acute migraine made by Pfizer Ltd has been recommended by the National Institute for Health and Care Excellence (NICE).
A partnership has been formed between Phesi and Krsytelis, born out of a need to address the lack of diversity in clinical trials.